A federal committee of cancer experts advising the Food and Drug Administration on Wednesday made it more likely Genentech's drug Avastin will no longer be readily available as a treatment for breast
cancer. In a series of 6-0 votes, the committee endorsed the agency's own proposal to revoke the approval of the drug for use against advanced breast cancer.
The researchers and
physicians voted that the drug was neither safe nor effective and unanimously rejected a proposed compromise offered by Genentech that the approval remain in place while the company conducts another
clinical trial to try to confirm that the drug works.
Read the whole story at The New York Times »